GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » Debt-to-Asset

Beijing Tiantan Biological Products (SHSE:600161) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products Debt-to-Asset?

Beijing Tiantan Biological Products's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥15 Mil. Beijing Tiantan Biological Products's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥28 Mil. Beijing Tiantan Biological Products's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥14,792 Mil. Beijing Tiantan Biological Products's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Beijing Tiantan Biological Products Debt-to-Asset Historical Data

The historical data trend for Beijing Tiantan Biological Products's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tiantan Biological Products Debt-to-Asset Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.11 0.04 0.03 -

Beijing Tiantan Biological Products Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 - -

Competitive Comparison of Beijing Tiantan Biological Products's Debt-to-Asset

For the Biotechnology subindustry, Beijing Tiantan Biological Products's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tiantan Biological Products's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Beijing Tiantan Biological Products's Debt-to-Asset falls into.



Beijing Tiantan Biological Products Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Beijing Tiantan Biological Products's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(17.951 + 24.415) / 14188.057
=0.00

Beijing Tiantan Biological Products's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(14.71 + 27.51) / 14791.832
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Tiantan Biological Products  (SHSE:600161) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Beijing Tiantan Biological Products Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Tiantan Biological Products (SHSE:600161) Business Description

Traded in Other Exchanges
N/A
Address
No. 4 Sanjianfang South Li, Zhongdan Center, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd is a China-based company engaged in the research and development, manufacturing, sales and consulting services for blood products. The company's blood products include Shanghai Blood Human Albumin, Shanghai blood system intravenous injection of human immunoglobulin, Guizhou blood human albumin, Rongsheng human albumin, Guizhou blood system static injection immunoglobulin, Rongsheng tetanus human immunoglobulin and others.
Executives
Wang Jian Ming Supervisors
Liu Ya Na Directors, senior managers
Fu Dao Xing Directors, senior managers
He Yan Lin Directors, senior managers
Hu Li Gang Director
Ci Xiang senior management
Yang Hui Chuan Director
Zhang Yi senior management
Wu Zhen Shan senior management

Beijing Tiantan Biological Products (SHSE:600161) Headlines

No Headlines